Therapeutic Solutions International, Inc., Appoints Juergen Winkler, MD, ABIHM to Scientific Advisory Board
Pioneer of Functional Medicine Teams Up with Clinical Stage Biotechnology Company in Commercialization of Non-Toxic Immunotherapy
OCEANSIDE, Calif., July 09, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire –Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today that Juergen Winkler, M.D., has been appointed to the Company’s Scientific Advisory Board.
Dr. Winkler is presently practicing at Quantum Functional Medicine in Carlsbad, CA, which he founded in 2012. Dr. Winkler has been a featured speaker for: the NSCC Women’s Health Seminar, Annual IPT/IPTLD Integrative Cancer Care Conference (Multiple years), Health Freedom Expo 2011 & 2012, the Japanese Society of Oxidative Medicine in Osaka Japan, ACOSPM 2010 & 2011 conferences, NSCC Health and Wellness Series 2013, and various other events. He is the physician author of Chapter 5 in “Defeat Cancer”, a book describing leading physicians on the forefront of the battle with Cancer.
“We are really excited to have Dr. Winkler join our team, working collaboratively with him in the background he has helped us to refine our latest product NanoStilbene, a nanoparticle formulation of pterostilbene, clinically shown to more effectively increase blood levels of the molecule as compared to conventional powder formulations”, said Timothy Dixon, President and CEO. “Dr. Winkler brings vast clinical experience in Functional Medicine, a way of looking at the root cause of a person’s disease and viewing each person as a unique individual to give his patients the best possible outcome in their care. Today we welcome Dr. Winkler aboard our distinguished Scientific Team,” added Mr. Dixon.
“The Team at Therapeutic Solutions International represents a highly synergistic group comprised of internationally renowned oncologists, immunologists, and business people dedicated to finding solutions for cancer in an unbiased and open-minded manner” said Dr. Winkler, adding “Having interacted with various Team members for over 2 years, I am highly enthusiastic about contributing to this deeply motivated group in their efforts to solve the problem of cancer.”
“The Functional Medicine perspective that Dr. Winkler brings to our group provides a fresh and highly innovative take on the oncological problems we deal with. Treatments such as intravenous vitamin C, which Dr. Winkler has been practicing for over a decade, and are only now being understood at a molecular level1. We hope to leverage Dr. Winkler’s experiences and insights in order to develop novel and non-toxic cancer immunotherapies.” said Dr. James Veltmeyer, Chief Medical Officer of the Company.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is www.therapeuticsolutionsint.com.
1 Lv et al. Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2.
NPJ Precis Oncol. 2018 Jan 8;2(1):1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871898/
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
- Therapeutic Solutions International, Inc.